Reviewing BioCryst Pharmaceuticals (NASDAQ:BCRX) and CytoDyn (OTCMKTS:CYDY)

BioCryst Pharmaceuticals (NASDAQ:BCRX) and CytoDyn (OTCMKTS:CYDY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, CytoDyn has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Profitability

This table compares BioCryst Pharmaceuticals and CytoDyn’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
CytoDyn	N/A	N/A	-182.93%

Earnings and Valuation

This table compares BioCryst Pharmaceuticals and CytoDyn”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72 million	2.85	$263.86 million	($1.78)	-5.58
CytoDyn	N/A	N/A	$3.74 million	($0.03)	-8.23

BioCryst Pharmaceuticals has higher revenue and earnings than CytoDyn. CytoDyn is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 5.1% of CytoDyn shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of CytoDyn shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for BioCryst Pharmaceuticals and CytoDyn, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0	3	9	0	2.75
CytoDyn	0	0	0	0	0.00

BioCryst Pharmaceuticals presently has a consensus target price of $20.70, suggesting a potential upside of 108.25%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than CytoDyn.

Summary

BioCryst Pharmaceuticals beats CytoDyn on 9 of the 13 factors compared between the two stocks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

About CytoDyn

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.